May 20, 2021 / 02:00PM GMT
Operator
Good afternoon, ladies and gentlemen, and welcome to the Veracyte management discussion of the Percepta Nasal Swab Test pivotal clinical validation data. As a reminder, today's conference is being recorded. I would now like to turn the conference over to Tracy Morris, Veracyte's Vice President of Corporate Communications and Investor Relations. You may begin.
Tracy Morris - Veracyte, Inc. - VP of Corporate Communications & IR
Thanks, Amanda. Good morning, everyone, and thanks for joining us today for a discussion of our Percepta Nasal Swab test pivotal clinical validation data, which we announced yesterday afternoon. With me today are Bonnie Anderson, Veracyte's Chairman and Chief Executive Officer; Dr. Giulia Kennedy, our Chief Scientific Officer and Chief Medical Officer; and Dr. Bill Bulman, our Medical Director for Lung Cancer.
Before we begin, I'd like to remind you that various statements that we may make during this call will include forward-looking statements as defined under applicable securities laws. Forward-looking statements include
Veracyte Inc to Discuss the Percepta Nasal Swab Test Pivotal Clinical Validation Data Conference Call Transcript
Feb 29, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers